Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib in Neoadjuvant TNBC
NCT02685657Phase 2Unknown
- Sponsor
- Russian Academy of Sciences
- Start
- Sep 2016
- Primary completion
- Jan 2018
01
Overview
Phase 2, randomised, open-label trial of selumetinib in triple-negative breast cancer (TNBC), sponsored by Russian Academy of Sciences. Status: unknown.
02
Drugs
selumetinib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02685657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02685657.